Get the Stockscreener App
164.53
1.95%
4.3598
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $164.53, with a volume of 1.59M.
It is up +1.95% in the last 24 hours and up +4.37% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$160.17
Open:
$164.08
24h Volume:
1.59M
Relative Volume:
0.50
Market Cap:
$254.87B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
49.41
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+0.36%
1M Performance:
+4.37%
6M Performance:
-14.01%
1Y Performance:
+105.24%
1-Day Range:
$162.14
$164.55
1-Week Range:
$156.74
$164.55
52-Week Range:
$72.89
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
164.34 | 248.41B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,149.43 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
268.45 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.47 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.16 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
139.75 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca stock holds steady amid licensing deal for novel Lp(a) inhibitor - ad-hoc-news.de
AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears - Yahoo Finance
AstraZeneca stock falls as Etcamah trial setback clouds oncology outlook - ad-hoc-news.de
AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long (NYSE:AZN) - Seeking Alpha
AstraZeneca breast cancer drug fails late-stage trial goal By Investing.com - Investing.com Nigeria
AstraZeneca's breast cancer pill fails in late-stage trial - Reuters
AstraZeneca's Etcamah fails in late-stage trial as first-line breast cancer treatment - Seeking Alpha
AstraZeneca stock falls after Etcamah trial setback despite strong oncology pipeline - ad-hoc-news.de
AstraZeneca Says Late-Stage Etcamah Breast-Cancer Trial Misses Main Goal - marketscreener.com
AstraZeneca breast cancer drug fails late-stage trial goal - investing.com
AstraZeneca Says Breast Cancer Pill Fails in Key Study - Bloomberg.com
AstraZeneca : Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer - marketscreener.com
Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer - AstraZeneca
Jim Cramer Says He Is Not Going to Put His Money on AstraZeneca (AZN) - Yahoo Finance
AstraZeneca Halts Early Lung Cancer Imaging Trial: What Investors Should Watch Next - TipRanks
Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca - Yahoo Finance
AstraZeneca stock gains as analysts see upside ahead of next earnings - ad-hoc-news.de
AstraZeneca stock heads into the open after a modest London gain - ad-hoc-news.de
AstraZeneca stock heads into the open after a 0.93% gain - ad-hoc-news.de
Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? - Yahoo Finance
AstraZeneca’s New Cholesterol Combo Trial Could Reshape Its Heart-Health Portfolio - TipRanks
Berenberg Notes AstraZeneca's 'Stellar' Tozorakimab Late-stage Data; Buy Retained - marketscreener.com
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche - Proactive financial news
AstraZeneca stock edges higher as Deutsche Bank sticks to Sell after COPD data - ad-hoc-news.de
AstraZeneca stock gains new RBC and Berenberg backing on COPD trial success - ad-hoc-news.de
AstraZeneca PLC : Gets a Sell rating from Deutsche Bank - marketscreener.com
Can AstraZeneca (LSE:AZN) Stock Extend Its Rally On A Fresh Wave Of Oncology Approvals? - Kalkine Media
AstraZeneca stock heads into the open after a modest September 9, 2026 gain - ad-hoc-news.de
AstraZeneca stock heads into the open after a 2.0 percent drop - ad-hoc-news.de
Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)? - Yahoo Finance
AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough - GuruFocus
AstraZeneca Advances TROP2 Testing Standard in Key Lung Cancer Study - TipRanks
AstraZeneca slips Wednesday, underperforms market - MarketWatch
AstraZeneca COPD data back Citi's $7b peak sales case - Proactive Investors
AstraZeneca stock gains analyst support as RBC sets 14,500p target - ad-hoc-news.de
RBC Capital Markets Initiates AstraZeneca Coverage at Outperform - marketscreener.com
AstraZeneca stock holds after RBC starts coverage at GBP145 - ad-hoc-news.de
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials - Reuters
RBC Initiates AstraZeneca at Outperform With GBP145 Price Target - marketscreener.com
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - Yahoo Finance
Amgen and AstraZeneca report survival improvement in lung cancer trial - Yahoo Finance UK
RBC Capital initiates AstraZeneca stock at Outperform, sets target at £145 By Investing.com - Investing.com Canada
RBC Initiates AstraZeneca at Outperform as Near-term Overhangs Create 'Attractive' Entry Point - marketscreener.com
Amgen and AstraZeneca report positive lung cancer trial results By Investing.com - Investing.com Nigeria
AstraZeneca stock edges lower ahead of the open after Imfinzi trial win - ad-hoc-news.de
Amgen and AstraZeneca report positive lung cancer trial results - investing.com
AstraZeneca Stock: What’s Shaping Investor Attention? - Kalkine Media
AstraZeneca stock heads into the open after a 1.2% slide - AD HOC NEWS
FDA clears Astrazeneca's Etcamah for first-line breast cancer - bioworld.com
AstraZeneca PLC : Gets a Buy rating from RBC - marketscreener.com
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):